Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
15 Preposterous Cosplay Ensembles That Will Blow You Away - 2Pick Your Number one sort of blossom
- 3Argentina reportedly delaying embassy move over Israeli company's oil project near Falklands
- 4Kissing is an ‘evolutionary conundrum.’ Scientists just mapped its unexpected origins
- 5Iran, Hezbollah fire rockets at Israel during Passover celebrations
- Find the Force of The ability to understand anyone on a deeper level: Improving Mindfulness and Connections
- The most effective method to Recuperate After a Dental Embed Strategy: A Far reaching Guide
- Israel says Iran's military industry will be destroyed 'within days'
- How stripping diversity, equity and inclusion from health care may make Americans sicker
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- BHP liable for 2015 Brazil mine disaster: UK court
- 5 Arising Professions in Environmentally friendly power
- Mosquitoes carrying malaria are evolving more quickly than insecticides can kill them – researchers pinpoint how
- Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance
